PCN84 COST-EFFECTIVENESS OF ERLOTINIB IN FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FIT ELDERLY PATIENTS- AN ECONOMICAL ANALYSIS OF A PROSPECTIVE PHASE 2 STUDY (GFPC 0504)
Abstract
Authors
C Chouaid H Lecaer J Crequit I Monnet S Chouabe C Locher D Paillotin JB Auliac P Thomas A Vergnenegre